iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

6 Months Ended

Dec. 31, 2023

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2023			2022			2023			2022
Basic and diluted numerator:

Net loss from continuing operations		$	(4,488)		$	(10,563)		$	(9,562)		$	(18,100)

Net loss from discontinued operations		$	(3,723)		$	(22,990)		$	(4,395)		$	(33,583)

Net loss - total		$	(8,211)		$	(33,553)		$	(13,957)		$	(51,683)

Basic and diluted denominator:

Weighted-average common shares outstanding			1,856			490			1,525			466

Per share amount - continuing operations		$	(2.42)		$	(21.54)		$	(6.27)		$	(38.82)
Per share amount - discontinued operations		$	(2.00)		$	(46.89)		$	(2.88)		$	(72.03)
Per share amount - total		$	(4.42)		$	(68.43)		$	(9.15)		$	(110.85)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		December 31,
		2023		2022

		(in thousands)
Stock options		36		36
Restricted stock units		3		11
Warrants		5,339		399
Shares excluded from the calculation of diluted loss per share		5,378		446